 Antiemetics
"Antiemetics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used to prevent NAUSEA or VOMITING.
| Descriptor ID |
D000932
|
| MeSH Number(s) |
D27.505.696.663.050.030 D27.505.954.427.095 D27.505.954.483.200
|
| Concept/Terms |
Antiemetics- Antiemetics
- Antiemetic Drugs
- Drugs, Antiemetic
- Anti-emetics
- Anti emetics
- Antiemetic Agents
- Agents, Antiemetic
Antiemetic Effect- Antiemetic Effect
- Effect, Antiemetic
- Anti-Emetic Effects
- Anti Emetic Effects
- Effects, Anti-Emetic
- Antiemetic Effects
- Effects, Antiemetic
- Anti-Emetic Effect
- Anti Emetic Effect
- Effect, Anti-Emetic
|
Below are MeSH descriptors whose meaning is more general than "Antiemetics".
Below are MeSH descriptors whose meaning is more specific than "Antiemetics".
This graph shows the total number of publications written about "Antiemetics" by people in this website by year, and whether "Antiemetics" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 0 | 1 | | 1993 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 5 | 0 | 5 | | 1998 | 4 | 0 | 4 | | 1999 | 2 | 1 | 3 | | 2001 | 1 | 0 | 1 | | 2002 | 3 | 1 | 4 | | 2003 | 3 | 0 | 3 | | 2004 | 4 | 0 | 4 | | 2005 | 1 | 2 | 3 | | 2006 | 3 | 0 | 3 | | 2007 | 3 | 1 | 4 | | 2008 | 1 | 0 | 1 | | 2009 | 3 | 0 | 3 | | 2010 | 2 | 0 | 2 | | 2011 | 2 | 0 | 2 | | 2013 | 1 | 2 | 3 | | 2014 | 3 | 0 | 3 | | 2015 | 3 | 1 | 4 | | 2016 | 8 | 2 | 10 | | 2017 | 3 | 0 | 3 | | 2018 | 3 | 1 | 4 | | 2019 | 5 | 1 | 6 | | 2020 | 5 | 2 | 7 | | 2021 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Antiemetics" by people in Profiles.
-
Chow R, Herrstedt J, Aapro M, Chiu L, Lam H, Prsic E, Lock M, DeAngelis C, Navari RM. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021 Jul; 29(7):3439-3459.
-
Chow R, Chiu L, Herrstedt J, Aapro M, Lock M, DeAngelis C, Navari RM. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients. Support Care Cancer. 2021 Aug; 29(8):4269-4275.
-
Navari RM, Ruddy KJ, LeBlanc TW, Nipp R, Clark-Snow R, Schwartzberg L, Binder G, Bailey WL, Potluri R, Schmerold LM, Papademetriou E, Roeland EJ. Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin. Oncologist. 2021 04; 26(4):325-331.
-
Aapro M, Navari RM, Roeland E, Zhang L, Schwartzberg L. Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies. Crit Rev Oncol Hematol. 2021 Jan; 157:103143.
-
Navari RM, Roeland EJ. Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies. Future Oncol. 2020 Aug; 16(24):1863-1872.
-
Navari RM, Pywell CM, Le-Rademacher JG, White P, Dodge AB, Albany C, Loprinzi CL. Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial. JAMA Oncol. 2020 06 01; 6(6):895-899.
-
Roeland EJ, Ruddy KJ, LeBlanc TW, Nipp RD, Binder G, Sebastiani S, Potluri R, Schmerold L, Papademetriou E, Schwartzberg L, Navari RM. What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy. J Natl Compr Canc Netw. 2020 06; 18(6):676-681.
-
Navari RM, Loprinzi CL. Olanzapine is an effective antiemetic agent. Ann Palliat Med. 2020 05; 9(3):628-630.
-
Navari RM. Nausea and Vomiting in Advanced Cancer. Curr Treat Options Oncol. 2020 02 05; 21(2):14.
-
Schwartzberg L, Navari R, Clark-Snow R, Arkania E, Radyukova I, Patel K, Voisin D, Rizzi G, Wickham R, Gralla RJ, Aapro M, Roeland E. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. Oncologist. 2020 03; 25(3):e589-e597.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|